Evidence map›Paper›PMID 41711974›Full record

ArticleAnnals of hematology2026

The optimal conditioning intensity of stem cell transplantation for acute myeloid leukemia in complete remission.

Yoshimitsu Shimomura, Sho Komukai, Tetsuhisa Kitamura, Tomotaka Sobue, Satoshi Yamasaki, Tadakazu Kondo, Shohei Mizuno, Kaito Harada, Naoki Shingai, Masatsugu Tanaka and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Yoshimitsu ShimomuraDepartment of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Minamimati 2-1-1, Minatojima, Chuo-ku, Kobe, 650-0047, Japan. shimomura_0119@yahoo.co.jp.
Sho KomukaiDivision of Biomedical Statistics Department of Integrated Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.
Tetsuhisa KitamuraDepartment of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Suita, Japan.
Tomotaka SobueDepartment of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Suita, Japan.
Satoshi YamasakiDepartment of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan.
Tadakazu KondoDepartment of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Minamimati 2-1-1, Minatojima, Chuo-ku, Kobe, 650-0047, Japan.
Shohei MizunoDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.
Kaito HaradaDepartment of Hematology and Oncology, Tokai University, Isehara, Japan.
Naoki ShingaiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Kanagawa, Japan.
Ayumu ItoDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Tetsuya NishidaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Aichi, Japan.
Hiroyuki OhigashiDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations TORANOMON HOSPITAL, Tokyo, Japan.
Ken-Ichi MatsuokaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Makoto OnizukaDepartment of Hematology, Tokai University School of Medicine, Kanagawa, Japan.
Toshiro KawakitaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Nobuhiro HiramotoDepartment of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Minamimati 2-1-1, Minatojima, Chuo-ku, Kobe, 650-0047, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Aichi, Japan.
Kentaro FukushimaDepartment of Hematology and Oncology, Osaka University Hospital, Suita, Japan.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takahiro FukudaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Aichi, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Masamitsu YanadaDepartment of Hematology and Oncology, Nagoya City University East Medical Center, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to identify patient groups in which myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) regimens induced superior progression-free survival (PFS) in patients with acute myeloid leukemia (AML) in complete remission (CR) using a machine-learning approach. Our study included 3273 patients aged 40–69 with AML in CR. The patients were divided into training (N = 2020) and validation cohorts (N = 1253). We employed a machine learning-based group identification model in the training cohort. Subsequently, in the validation cohort, we estimated the impact of the optimal conditioning group compared with the non-optimal conditioning group on PFS using an inverse probability weight analysis. The developed model was consistent with the eight factors and combinations, and the high score suggested that RIC was more appropriate than MAC. In the validation cohort, 127 patients with high scores and who received RIC and 769 patients with low scores and who received MAC were categorized into the optimal conditioning group (896, 71.5%). The weighted hazard ratio for PFS was 0.73 (95% confidence interval: 0.57–0.94) in the optimal conditioning group compared with the non-optimal conditioning group (P = 0.016). In conclusion, we developed an easy-to-use model that helps the physician choose a patient-specific conditioning regimen for patients with AML in CR.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteTransplantation ConditioningAdultAgedFemaleHumansMachine LearningMaleMiddle AgedRemission InductionAcute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationAnd myeloablative conditioning regimenComplete remissionReduced intensity conditioning regimen

Identifiers

PMID41711974
PMCPMC12920725

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.